Skip to main content

LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test

Written by Customer Service on . Posted in Public Companies.

Company receives $14.2M in grants from the Bill & Melinda Gates Foundation to support the TB test’s ongoing development and future launch into developing countries

LONDON, Dec. 14, 2022 (GLOBE NEWSWIRE) — LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced it has received $14.2M in grants from the Bill & Melinda Gates Foundation for ongoing development of its point of care molecular tuberculosis (TB) testing system. Used with the LumiraDx multi-assay Platform, the molecular TB test is being developed to provide highly accurate results at a low price at the point of care enabling clinicians to immediately commence appropriate treatment and patient management to maximize health outcomes and minimize further spread of infection.

According to the World Health Organization’s 2022 Global Tuberculosis Report, the difference in the number of people who were infected with TB and the number of people diagnosed with TB widened in both 2020 and 2021 versus 2019 to over 4 million each year. To address this crisis, a substantial new supply of molecular TB tests is required. However, existing options are limited by price, test run time, electricity requirements as well as a reliance on a sputum sample type, which can be challenging to collect from many patients.

The LumiraDx molecular TB test is designed to fill these gaps and needs in the TB testing market and significantly increase access to testing. With support from the foundation, the testing system is being developed to provide testing at a lower cost and incorporate a tongue swab sample which makes it easier for a higher percentage of patients to be tested. In addition, the portability of the LumiraDx Platform, which weighs only 1.1kg, and uses a rechargeable battery, would allow the TB test to be used in decentralized settings across low and middle-income countries where lab access is limited. The LumiraDx Platform, is the only point of care instrument that supports both molecular and immunoassay technologies.

Ron Zwanziger, LumiraDx CEO commented, “The advancement of our TB molecular test signifies an important step forward in LumiraDx’s mission to increase access to accurate and affordable testing worldwide as well as an important step forward in our molecular testing technology. The support from the Gates Foundation is critical in our development of the TB test and ensuring it reaches communities where access to testing is most challenged. The availability of these immediate results can be game changing.”

The LumiraDx platform is designed to run a variety of sample types and technology with 12 tests currently available. The TB test is the first molecular test the company has developed for the point of care Platform. LumiraDx has already initiated testing of the TB molecular test in pre-clinical studies in Africa.

About LumiraDx
LumiraDx Limited (Nasdaq: LMDX) is a next-generation point of care diagnostics company that is transforming community-based healthcare. Its actively controlled microfluidic technology provides fast, high performance and accessible diagnostic solutions wherever the patient is for nearly any testing scenario, creating unique testing options at the point of need.

The company offers a broad menu of lab comparable tests on a single portable Platform, with more than 30 assays on the market and in the pipeline, covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders. The company also supports high-complexity laboratory testing in an accessible high-throughput format to leverage current molecular laboratory operations.

Founded in 2014 and based in the UK, LumiraDx’s diagnostic testing solutions are being deployed globally by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to help screen, diagnose, and monitor wellness as well as disease.
More information on LumiraDx is available at www.lumiradx.com. 

Media Contact: 
Colleen.McMillen@lumiradx.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.